Clinical trials: Tumor Burden
Inherited Epidermolysis Bullosa, Ichthyosis
FARD (RaDiCo Cohort) (RaDiCo-FARD)
The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical)…
- Conditions
- Inherited Epidermolysis Bullosa, Ichthyosis, Ectodermal Dysplasia, Incontinentia Pigmenti
- Trial name
- FARD (NCT05954416)
- Where
- 15 sites in France
- Volunteers
- 900 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Cancer, Financial Burden
Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS)
Screening and referral program to proactively identify financial hardship in adult patients with cancer and connect those at-risk with education, counseling, and resources.
- Conditions
- Cancer, Financial Burden, Financial Toxicity, Screening Tool
- Trial name
- I-ACCESS (NCT07664436)
- Testing
- Financial counseling and navigation
- Where
- 4 sites in United States
- Volunteers
- 220 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cancer, Neoplasms
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
New oral anticancer treatments have improved survival across cancer types but introduced challenges in medication adherence and symptom management.
- Trial name
- SMART pilot (NCT07073807)
- Testing
- SMART Intervention using TAPPT® for Adherence, Symptom, Financial, and Social Needs Monitoring
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Skin Cancer
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Objectives: The objective of this study is to develop a valid and reliable measure of the symptom burden experienced by patients with cancer experiencing disease-related skin problems and to delineate this burden over time.
- Trial name
- NCT01193036
- Testing
- Part 1: Interview + Questionnaires, Part 2: Multiple Questionnaires
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Symptom Burden in Chronic Myeloid Leukemia (CML)
Objectives: The objective of this study is to measure and delineate the symptom burden experienced by patients with chronic myeloid leukemia (CML). The Primary Aim is to develop and validate an M. D.
- Trial name
- NCT01046305
- Testing
- Interview & Questionnaires, Rating Questionnaire, MDASI-CML Questionnaire
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature…
- Trial name
- RADICAL (NCT05253495)
- Testing
- DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- New York Medical College
Head and Neck Cancer Patients, Late Effects
Use of Computer-based Patient-reported Data to Assess Long Term and Late Effects of Head and Neck Cancer at the Point-of-care
Patient-reported information on outcomes such as symptom-burden and health-related quality of life (QoL) is regarded as a useful tool to improve quality of care in clinical cancer research.
- Trial name
- NCT01803061
- Testing
- WebCan
- Where
- 2 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Danish Cancer Society
Ovarian Cancer
M. D. Anderson Symptom Inventory - Ovarian Cancer
Objectives: The objective of this study is to delineate and measure the symptom burden experienced by patients with ovarian cancer. The Primary Aim is to develop and validate an ovarian-cancer module of the M. D.
- Trial name
- NCT01037751
- Testing
- Interview, Survey
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of…
- Trial name
- NCT01048983
- Testing
- Armodafinil, Bupropion, Minocycline
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
- Trial name
- NCT00582166
- Testing
- Ibritumomab Tiuxetan (Zevalin) + Rituximab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Cancer, Breast Cancer
Improving Survivorship Among Minority Cancer Dyads
This proposed intervention centers on improving survivorship outcomes among African American and Latinx cancer survivor and caregiver dyads. As a result, there will be four major outcomes.
- Conditions
- Cancer, Breast Cancer, Colon Cancer, Caregiver Burnout
- Trial name
- NCT04685551
- Testing
- Change in knowledge, motivation, skills, and resources
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
Solid Tumors
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
This study is being conducted to evaluate efficacy parameters (disease free survival [DFS] and overall survival [OS]) of atezolizumab and atezolizumab in combination with tiragolumab in TMB-H or MSI-H as adjuvant treatment after…
- Trial name
- IMperator (NCT06331598)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 3 sites in Spain
- Sponsor
- Hoffmann-La Roche
Cancer
Burden of Cancer in Children: A Pilot Study to Investigate the Impact and Content of Video Illness Narratives
In order to gain a greater understanding of the full experience of children with life-threatening illness, this study will provide video cameras to ten to fifteen 10-18 years olds in active treatment for cancer, and instruct them…
- Trial name
- NCT00793299
- Testing
- Video Illness Narrative
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Rochester
Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage…
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06632106
- Testing
- hepatic artery infusion chemotherapy, Tyrosine kinase inhibitor (TKIs), Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Hospital of China Medical University
Colorectal Cancer
Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
The goal of this clinical research study is to learn if minocycline can reduce numbness, pain, and/or loss of motor function in patients with colorectal cancer. In this study, minocycline will be compared to a placebo.
- Trial name
- NCT01906008
- Testing
- Minocycline, Questionnaires, Sensory Test
- Where
- 2 sites in United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured patients (age >= 18 years and < 65 years).
- Trial name
- NCT01381614
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Renal Cell Carcinoma
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
- Trial name
- NCT04883827
- Testing
- Blood collection, Urine collection
- Where
- 3 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Primary Brain Tumor, Caregiver Burden
The Effect of Home Care Planned According to Orem in Patients With Primary Brain Tumor and Their Caregivers
This study was conducted to evaluate the effect of home care planned according to Orem on self-care agency and care burden in brain tumor patients and their caregivers.
- Conditions
- Primary Brain Tumor, Caregiver Burden, Self Care
- Trial name
- NCT05328739
- Testing
- home care
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Bone Tumor, Bone Cancer
Medical Payment Case Management for Financial Toxicity in Patients With Primary Bone Tumors: A Randomized Controlled Trial
The goal of this clinical trial is to learn if adding a medical payment case management service to the hospital's usual follow-up care can reduce the financial hardship of cancer treatment in patients of any age, including…
- Trial name
- NCT07888244
- Testing
- Medical payment case management service
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Shanghai 6th People's Hospital
Ovarian Neoplasms, Fallopian Tube Neoplasms
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site
- Trial name
- AVANIRA3 (NCT04556071)
- Testing
- Niraparib, Bevacizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xiaoxiang Chen